Tag Archives: michigan-comprehensive

Changing chemo not beneficial for metastatic breast cancer patients with elevated circulating tumor cells

"We concluded that CTCs are not a good marker in helping to decide when to switch between chemotherapies," said Jeffrey B. Smerage, M.D., Ph.D., clinical associate professor at the University of Michigan Comprehensive Cancer Center in Ann Arbor. "It had been hoped that switching would both increase the chances of being on an effective therapy and decrease the exposure to toxicity from less effective or ineffective therapies, and as a result it had been hoped that this early switching would result in improved survival and time to progression. "The most important implication is that we have validated that the group of patients with elevated CTCs at both baseline and 21 days [after starting their first chemotherapy] has a worse prognosis with regard to both time to progression and overall survival," added Smerage…

Clinical trial tests new treatment for rare cancer

Now adrenal cancer researchers at the University of Michigan Comprehensive Cancer Center are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients. Researchers Tom Kerppola, Ph.D., and Gary Hammer, M.D., Ph.D., collaborated to test a new compound, ATR-101, in cell lines and mice. …